Chimerix (CMRX) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMRX shares.
View CMRX analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12 month price objectives for Chimerix's stock. Their CMRX share price forecasts range from $7.00 to $11.00. On average, they expect the company's stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 474.7% from the stock's current price.
View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts.

Chimerix's stock was trading at $1.86 at the beginning of 2023. Since then, CMRX stock has decreased by 22.0% and is now trading at $1.45.
View the best growth stocks for 2023 here.

Chimerix saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 3,720,000 shares, a drop of 9.3% from the April 30th total of 4,100,000 shares. Based on an average trading volume of 945,700 shares, the short-interest ratio is presently 3.9 days. Approximately 5.0% of the shares of the company are sold short.
View Chimerix's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CMRX earnings forecast.

Chimerix, Inc. (NASDAQ:CMRX) announced its quarterly earnings data on Thursday, March, 2nd. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.24). The biopharmaceutical company had revenue of $0.81 million for the quarter, compared to analysts' expectations of $2.60 million. Chimerix had a trailing twelve-month return on equity of 87.89% and a net margin of 514.97%. During the same quarter last year, the company earned ($0.45) EPS.

ETFs with the largest weight of Chimerix (NASDAQ:CMRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and ETFMG Treatments Testing and Advancements ETF (GERM) and

Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD).

Chimerix trades on the NASDAQ under the ticker symbol "CMRX."

Chimerix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Rubric Capital Management LP (8.28%), BlackRock Inc. (5.52%), Armistice Capital LLC (3.70%), State Street Corp (2.59%), Acadian Asset Management LLC (2.25%) and AQR Capital Management LLC (2.15%). Insiders that own company stock include David Jakeman, Fred A Middleton, Martha J Demski, Michael T Andriole and Robert J Meyer.
View institutional ownership trends.

Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CMRX stock can currently be purchased for approximately $1.45.

Chimerix (NASDAQ:CMRX) has a market capitalization of $128.44 million and generates $33.82 million in revenue each year. The biopharmaceutical company earns $172.17 million in net income (profit) each year or $2.00 on an earnings per share basis.

Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146.